SARS-CoV-2 mRNA Vaccines Induce Cross-Reactive Antibodies to NL63 Coronavirus but do not Boost Pre-Existing Immunity Anti-NL63 Antibody Responses

• DOI: 10.20944/preprints202502.1767.v1
• Publication Date: 2025-02-24T02:48:42Z
• Authors: Tang Weiyi; Chang Zi Wei; Goh Yun Shan; Tan Yong Jie; Hor Pei Xiang; Loh Chiew Yee; Lye C David; Young E Barnaby; Ng FP Lisa; Tay Zirui Matthew; Renia Laurent
• Keywords: Coronavirus; 2019-20 coronavirus outbreak; Antibody response

MRNA vaccines have been shown to provide strong immune responses against SARS-CoV-2, but the extent of their antibody cross-reactivity human seasonal coronaviruses, such as NL63, remains unclear. Furthermore, it is unknown whether pre-existing NL63 might affect outcome SARS-CoV-2 mRNA vaccination. This study used a flow cytometry-based serological assay and an in vitro neutralization analyze sera from mRNA-vaccinated mice plasma samples vaccinated cohort. We found that Moderna mRNA-1273 vaccine can generate cross-reactive antibodies NL63. Importantly, vaccination did not boost anti-NL63 humans, levels response induced by These findings suggest while induce immunity this coronavirus does appear significantly impact effectiveness vaccine. contributes our understanding complex interplay between coronaviruses generated vaccines.